Compare ANET & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANET | NVO |
|---|---|---|
| Founded | 2004 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.2B | 212.7B |
| IPO Year | 2014 | N/A |
| Metric | ANET | NVO |
|---|---|---|
| Price | $130.01 | $62.22 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 10 |
| Target Price | ★ $163.93 | $54.25 |
| AVG Volume (30 Days) | 6.7M | ★ 19.2M |
| Earning Date | 02-17-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 2.15% |
| EPS Growth | ★ 26.15 | 10.06 |
| EPS | 2.63 | ★ 3.67 |
| Revenue | $8,448,346,000.00 | ★ $49,580,393,058.00 |
| Revenue This Year | $29.46 | $7.25 |
| Revenue Next Year | $21.86 | $0.24 |
| P/E Ratio | $49.66 | ★ $15.58 |
| Revenue Growth | ★ 27.75 | 16.64 |
| 52 Week Low | $59.43 | $43.08 |
| 52 Week High | $164.94 | $93.80 |
| Indicator | ANET | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 72.64 |
| Support Level | $120.00 | $56.29 |
| Resistance Level | $133.34 | $60.63 |
| Average True Range (ATR) | 4.67 | 1.44 |
| MACD | -0.02 | 0.59 |
| Stochastic Oscillator | 46.10 | 96.28 |
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.